Sentiment-Signal
13,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 24.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 26.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | he Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa |
| 09.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointme |
| 05.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | orm 8-K and is incorporated by reference in this Item 5.02. Item 7.01 Regulation FD Disclosure. On September 5, 2023, th |
Stammdaten
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Unternehmen & Branche
| Name | Invivyd, Inc. |
|---|---|
| Ticker | IVVD |
| CIK | 0001832038 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 181,0 Mio. USD |
| Beta | 0,74 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 53,426,000 | -52,489,000 | -0.30 | 276,883,000 | 241,540,000 |
| 2025-09-30 | 10-Q | 13,129,000 | -10,470,000 | -0.06 | 139,158,000 | 93,068,000 |
| 2025-06-30 | 10-Q | 11,786,000 | -14,660,000 | -0.12 | 89,138,000 | 42,789,000 |
| 2025-03-31 | 10-Q | 11,304,000 | -16,289,000 | -0.14 | 103,744,000 | 54,149,000 |
| 2024-12-31 | 10-K | 25,384,000 | -169,925,000 | -1.43 | 129,515,000 | 67,539,000 |
| 2024-09-30 | 10-Q | 9,300,000 | -60,739,000 | -0.51 | 161,922,000 | 83,161,000 |
| 2024-06-30 | 10-Q | 2,264,000 | -47,247,000 | -0.40 | 177,346,000 | 140,642,000 |
| 2024-03-31 | 10-Q | 0 | -43,496,000 | -0.38 | 215,468,000 | 178,498,000 |
| 2023-12-31 | 10-K | 0 | -198,643,000 | -1.81 | 229,181,000 | 177,468,000 |
| 2023-09-30 | 10-Q | 0 | -39,440,000 | -0.36 | 274,917,000 | 246,499,000 |
| 2023-06-30 | 10-Q | 0 | -50,228,000 | -0.46 | 315,414,000 | 281,563,000 |
| 2023-03-31 | 10-Q | -35,321,000 | -0.32 | 350,564,000 | 326,749,000 | |
| 2022-12-31 | 10-K | -241,317,000 | -2.23 | 383,167,000 | 355,970,000 | |
| 2022-09-30 | 10-Q | -45,087,000 | -0.42 | 424,747,000 | 377,443,000 | |
| 2022-06-30 | 10-Q | -50,990,000 | -0.47 | 484,612,000 | 414,839,000 | |
| 2022-03-31 | 10-Q | -100,666,000 | -0.93 | 556,273,000 | 459,392,000 | |
| 2021-12-31 | 10-K | -83,042,000 | -5.32 | 620,091,000 | 558,019,000 | |
| 2021-09-30 | 10-Q | -60,375,000 | -0.98 | 686,270,000 | 633,213,000 | |
| 2021-09-30 | 10-K | -60,375,000 | ||||
| 2021-06-30 | 10-Q | -44,673,000 | -178.86 | 397,992,000 | -144,624,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Allen Robert D. III | Officer, Chief Scientific Officer | Open Market Sale | -19,392 | 1.58 | -30,596.70 | -99,5% | |
| 2026-02-18 | Andersen Jill | Officer, Chief Legal Officer, Secretary | Open Market Sale | -34,939 | 1.58 | -55,126.75 | -179,2% | |
| 2026-02-18 | Lee Timothy Edward | Officer, Chief Commercial Officer | Open Market Sale | -20,964 | 1.58 | -33,077.00 | -107,5% | |
| 2026-02-18 | Green Julie | Officer, Chief Human Resources Officer | Open Market Sale | -20,964 | 1.58 | -33,077.00 | -107,5% | |
| 2026-02-18 | Duke William E. | Officer, Chief Financial Officer | Open Market Sale | -20,964 | 1.58 | -33,077.00 | -107,5% | |
| 2026-02-17 | Duke William E. | Officer, Chief Financial Officer | Open Market Sale | -19,663 | 1.54 | -30,273.15 | -98,4% | |
| 2026-02-17 | Green Julie | Officer, Chief Human Resources Officer | Open Market Sale | -19,663 | 1.54 | -30,273.15 | -98,4% | |
| 2026-02-17 | Andersen Jill | Officer, Chief Legal Officer, Secretary | Open Market Sale | -32,771 | 1.54 | -50,454.23 | -164,0% | |
| 2026-02-17 | Allen Robert D. III | Officer, Chief Scientific Officer | Open Market Sale | -18,189 | 1.54 | -28,003.78 | -91,0% | |
| 2026-02-17 | Lee Timothy Edward | Officer, Chief Commercial Officer | Open Market Sale | -19,663 | 1.54 | -30,273.15 | -98,4% | |
| 2025-11-19 | MCLAUGHLIN KEVIN F | Director | Open Market Purchase | 50,000 | 2.50 | 125,000.00 | +406,4% | |
| 2025-08-19 | Allen Robert D. III | Officer, Chief Scientific Officer | Open Market Sale | -27,420 | 0.57 | -15,536.17 | -50,5% | |
| 2025-08-19 | Andersen Jill | Officer, Chief Legal Officer, Secretary | Open Market Sale | -49,402 | 0.57 | -27,991.17 | -91,0% | |
| 2025-08-19 | Lee Timothy Edward | Officer, Chief Commercial Officer | Open Market Sale | -29,643 | 0.57 | -16,795.72 | -54,6% | |
| 2025-08-19 | Green Julie | Officer, Chief Human Resources Officer | Open Market Sale | -29,643 | 0.57 | -16,795.72 | -54,6% | |
| 2025-08-19 | Duke William E. | Officer, Chief Financial Officer | Open Market Sale | -29,643 | 0.57 | -16,795.72 | -54,6% | |
| 2025-08-18 | Duke William E. | Officer, Chief Financial Officer | Open Market Sale | -20,013 | 0.65 | -13,012.45 | -42,3% | |
| 2025-08-18 | Green Julie | Officer, Chief Human Resources Officer | Open Market Sale | -20,013 | 0.65 | -13,012.45 | -42,3% | |
| 2025-08-18 | Andersen Jill | Officer, Chief Legal Officer, Secretary | Open Market Sale | -33,352 | 0.65 | -21,685.47 | -70,5% | |
| 2025-08-18 | Allen Robert D. III | Officer, Chief Scientific Officer | Open Market Sale | -18,512 | 0.65 | -12,036.50 | -39,1% | |
| 2025-08-18 | Lee Timothy Edward | Officer, Chief Commercial Officer | Open Market Sale | -20,013 | 0.65 | -13,012.45 | -42,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.